Disruption in the gastric motility can lead to serious medical conditions. The prokinetic drugs aid in restoring the rhythmic muscle contractions or peristalsis responsible for gastric emptying and motility. Growing prevalence of gastrointestinal disorders and rising need for managing gastric motility issues are major factors fueling the demand for gastric motility disorder drugs.

The Global Gastric Motility Disorder Drug Market is estimated to be valued at US$ 83.15 Bn in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period from 2024 to 2031.

Key Takeaways

Key players operating in the gastric motility disorder drug market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila Pharmaceuticals.

The rising prevalence of gastrointestinal disorders, increasing demand for non-invasive treatment options, and growing awareness regarding gastric disorders are fueling the growth of the gastric motility disorder drug market. According to the World Gastroenterology Organisation, over 2 million individuals worldwide are affected by gastrointestinal motility disorders annually.

Key players are focusing on expansion in high growth markets through acquisitions and collaborations. Manufacturers are also investing in developing novel drug formulations and delivery systems to provide cost-effective treatment options for gastric motility disorders. For instance, in 2020, Evoke Pharma and EVERSANA entered into an agreement for commercializing Gimoti in the United States. Such expansions are expected to surge the demand for gastric motility disorder drugs globally.

Market Drivers

The increasing healthcare expenditure per capita and growing emphasis on research & development activities for gastrointestinal disorders are expected to drive the gastric motility disorder drug market. Additionally, changing lifestyle, rising consumption of unhealthy food, increase in stress levels, and growing geriatric population are some other factors projected to propel the demand for gastric motility disorder medications over the forecast period. However, side effects associated with certain prokinetic drugs and lack of established treatment options for rare gastric motility disorders may impede the market growth.